

ONGOING CLINICAL TRIALS (ACTIVE RECRUITMENT)

No.	Protocol ID	Study Title	Investigator(s)
1.	OXFORD	Validation of Chromosomal Conformation Signatures in Patients Undergoing Cancer Immunotherapy	Dr Hayani Abd Wahid/ Dr Sanjeev
2.	ELEGANT	Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)	Dr Sanjeev/Dr Hayani Abd Wahid
3.	EvoPAR-Breast01	Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer	Dr Sanjeev/Dr Hayani Abd Wahid

End of Recruitment

No.	Protocol ID	Study Title	Investigator(s)
1.	CAMBRIA-1	A Study of Camizestrant in ER+/HER2- Early Breast Cancer after at least 2 years of Standard Adjuvant Endocrine-Based	Dr Sanjeev/Dr Hayani Abd Wahid
2.	JIMMY LUNG	A randomized, double-blind, parallel-group study to compare efficacy, safety, and immunogenicity of GME751 (proposed pembrolizumab biosimilar) and EU-authorized Keytruda® in adult participants with untreated metastatic non-squamous non-small cell lung cancer (NSCLC)	Dr Sanjeev/Dr Hayani Abd Wahid
3.	JIMMY MELANOMA	A PK study to compare GME751 (proposed pembrolizumab biosimilar) and US-licensed and EU-authorized Keytruda® in participants with Stage II and III Melanoma in the adjuvant	Dr Sanjeev/Dr Hayani Abd Wahid